Roche complements haemostasis portfolio with Multiplate analyser
Roche has started the distribution of the Multiplate analyser, a system for the rapid determination of a patient's platelet function. The Multiplate analyser aids health professionals to predict a patient's thrombotic and bleeding risk and thus enables them to tailor antiplatelet therapies and to stratify patients at risk of bleeding during and after surgery.
Patients with high residual on-treatment reactivity have been shown to be at increased risk of stroke and recurrent ischaemic events. Platelet inhibitors such as Aspirin and clopidogrel are used to ensure blood fluidity and to minimise the formation of thrombi, but not all patients respond well to anti-thrombotic agents. For example, up to 25 per cent of patients only respond inadequately to a treatment with the platelet anti-aggregant clopidogrel. They are termed non-responders. The identified increased risk can be reduced by switching these patients to other antiplatelet therapies that have been shown to reduce recurrent events.
With patients under antiplatelet therapy like Aspirin, it is crucial to assess the patients' bleeding risk before surgical impacts. As Aspirin is commonly known for a tendency of mild bleeding, the treatment of patients with additional anti-thrombotic agents such as clopidogrel showed a perioperative risk of bleeding. Multiplate supports health professionals with a precedent patient monitoring to determine if the individual is at risk of severe bleeding when treated with specific anti-thrombotic agents. Several studies have shown that Multiplate analysis can successfully determine the effectiveness of anti-platelet drugs like Aspirin, as well as antiplatelet treatment options like clopidogrel and prasugrel.
A major challenge in patients with intravascular stent implants is that the turbulent surface of the implant can activate platelet formation. Consequently, a pharmacological platelet inhibition is crucial to prevent stent thrombosis. In clinical practice a dual platelet aggregation treatment is currently recommended to avoid thrombi forming. However, challenges with non-responders on specific anti-thrombotic agents exist. In one of the largest clinical investigations to date, poor clopidogrel responders had a 9.4 fold higher risk of stent thrombosis than normal responders, whilst the proportion of patients resistant to Aspirin is about one out of ten. Several studies showed that routine tailoring of antiplatelet therapy using Multiplate testing has the potential to significantly reduce the incidence of major adverse ischaemic events after coronary stent implantation.
Laboratory coagulation is estimated to be the fifth largest market in professional diagnostics worldwide. By the year of 2015, Roche expects a significant growth in the field of coagulation diagnostics of above 5 per cent in a global US$1.3 billion market. First deployed in the European, Middle-East and Asian region the system comes with six CE-marked reagents, including the ADPtest, ASPItest, TRAPtest, COLtest, RISTOtest and ADPtest HS.